AG˹ٷ

STOCK TITAN

[S-8] Armata Pharmaceuticals, Inc. Employee Benefit Plan Registration

Filing Impact
(No impact)
Filing Sentiment
(Neutral)
Form Type
S-8
Rhea-AI Filing Summary

Armata Pharmaceuticals filed a Form S-8 to register an additional 1,811,295 shares of common stock for issuance under its 2016 Equity Incentive Plan and 2016 Employee Stock Purchase Plan. The shares break down into 1,809,153 shares added under the Equity Incentive Plan and 2,142 shares under the ESPP pursuant to annual "evergreen" provisions that operate from January 1, 2017 through January 1, 2026. The filing incorporates prior S-8 registration statements and recent SEC filings, including the Annual Report for the year ended December 31, 2024 and quarterly reports for March 31, 2025 and June 30, 2025. The Registration Statement was signed on August 13, 2025 by Chief Executive Officer Deborah L. Birx.

Armata Pharmaceuticals ha depositato un modulo S-8 per registrare ulteriori 1,811,295 azioni ordinarie da emettere nell'ambito del suo 2016 Equity Incentive Plan e del 2016 Employee Stock Purchase Plan. Le azioni si suddividono in 1,809,153 azioni aggiuntive per l'Equity Incentive Plan e 2,142 azioni per l'ESPP, in base alle disposizioni annuali 'evergreen' vigenti dal 1 gennaio 2017 al 1 gennaio 2026. Il deposito incorpora precedenti dichiarazioni di registrazione S-8 e documenti SEC recenti, compreso il rapporto annuale relativo all'esercizio chiuso il 31 dicembre 2024 e i rapporti trimestrali al 31 marzo 2025 e al 30 giugno 2025. La dichiarazione di registrazione è stata firmata il 13 agosto 2025 dall'amministratore delegato Deborah L. Birx.

Armata Pharmaceuticals presentó un Formulario S-8 para registrar un adicional 1,811,295 acciones ordinarias para emisión bajo su 2016 Equity Incentive Plan y 2016 Employee Stock Purchase Plan. Las acciones se desglosan en 1,809,153 acciones añadidas al Equity Incentive Plan y 2,142 acciones bajo el ESPP conforme a las disposiciones anuales 'evergreen' vigentes desde el 1 de enero de 2017 hasta el 1 de enero de 2026. La presentación incorpora declaraciones de registro S-8 anteriores y presentaciones recientes ante la SEC, incluido el Informe Anual correspondiente al ejercicio cerrado el 31 de diciembre de 2024 y los informes trimestrales del 31 de marzo de 2025 y del 30 de junio de 2025. La declaración de registro fue firmada el 13 de agosto de 2025 por la directora ejecutiva Deborah L. Birx.

Armata Pharmaceuticals� Form S-8� 제출하여 2016� 주식 인센티브 플랜 � 2016� 종업� 주식매입계획(ESPP)� 따라 추가 보통� 1,811,295주를 등록했습니다. 주식은 인센티브 플랜� 추가� 1,809,153주와 ESPP� 따른 2,142주로 구분되며, 이는 2017� 1� 1일부� 2026� 1� 1일까지 적용되는 연간 'evergreen' 규정� 따른 것입니다. 이번 제출에는 이전 S-8 등록서류와 최근 SEC 제출서류가 포함되며, 2024� 12� 31� 종료� 회계연도 연례보고서와 2025� 3� 31� � 2025� 6� 30� 분기보고서가 포함됩니�. 등록서류� 최고경영�(CEO) 데보� L. 버릭스가 2025� 8� 13� 서명했습니다.

Armata Pharmaceuticals a déposé un formulaire S-8 pour enregistrer 1,811,295 actions ordinaires supplémentaires à émettre au titre de son 2016 Equity Incentive Plan et de son 2016 Employee Stock Purchase Plan. Ces actions se répartissent en 1,809,153 actions ajoutées à l'Equity Incentive Plan et 2,142 actions pour le ESPP, conformément aux dispositions annuelles 'evergreen' en vigueur du 1er janvier 2017 au 1er janvier 2026. Le dépôt incorpore des déclarations S-8 antérieures et des documents récents déposés auprès de la SEC, notamment le rapport annuel pour l'exercice clos le 31 décembre 2024 et les rapports trimestriels au 31 mars 2025 et au 30 juin 2025. La déclaration d'enregistrement a été signée le 13 août 2025 par la directrice générale Deborah L. Birx.

Armata Pharmaceuticals reichte ein Formular S-8 ein, um zusätzlich 1,811,295 Stammaktien zur Ausgabe im Rahmen ihres 2016 Equity Incentive Plan und des 2016 Employee Stock Purchase Plan zu registrieren. Die Aktien verteilen sich auf 1,809,153 Aktien, die dem Equity Incentive Plan hinzugefügt werden, und 2,142 Aktien für das ESPP gemäß den jährlichen 'evergreen'-Bestimmungen, die vom 1. Januar 2017 bis zum 1. Januar 2026 gelten. Die Einreichung bezieht frühere S-8-Registrierungserklärungen und jüngste SEC-Meldungen ein, darunter den Jahresbericht für das zum 31. Dezember 2024 endende Geschäftsjahr sowie die Quartalsberichte zum 31. März 2025 und zum 30. Juni 2025. Die Registrierungsanzeige wurde am 13. August 2025 von der Geschäftsführerin Deborah L. Birx unterzeichnet.

Positive
  • Registers an additional 1,811,295 shares for employee compensation plans, maintaining capacity for equity awards
  • Confirms evergreen provisions under both the 2016 Equity Incentive Plan and the 2016 ESPP through January 1, 2026, enabling automatic annual increases
Negative
  • None.

Insights

TL;DR: Routine S-8 registration adds 1.81M shares to support employee compensation; no earnings or transactional changes disclosed.

The filing is a standard update to employee equity capacity, registering 1,811,295 additional shares under existing plans. The majority (1,809,153) arises from the Equity Incentive Plan's evergreen formula and 2,142 from the ESPP’s annual cap. The statement incorporates recent SEC filings, but contains no new financial results, debt changes, or material transactions that would immediately affect valuation.

TL;DR: Governance mechanics intact: board-authorized evergreen increases and standard incorporation-by-reference of prior filings.

The document relies on General Instruction E to add shares for existing employee plans and references the evergreen provisions that automatically increase authorized shares annually through January 1, 2026. Signatures and a power of attorney are included, with the CEO certifying the filing on August 13, 2025. This is a procedural governance filing rather than a corporate-control or compensation-policy change.

Armata Pharmaceuticals ha depositato un modulo S-8 per registrare ulteriori 1,811,295 azioni ordinarie da emettere nell'ambito del suo 2016 Equity Incentive Plan e del 2016 Employee Stock Purchase Plan. Le azioni si suddividono in 1,809,153 azioni aggiuntive per l'Equity Incentive Plan e 2,142 azioni per l'ESPP, in base alle disposizioni annuali 'evergreen' vigenti dal 1 gennaio 2017 al 1 gennaio 2026. Il deposito incorpora precedenti dichiarazioni di registrazione S-8 e documenti SEC recenti, compreso il rapporto annuale relativo all'esercizio chiuso il 31 dicembre 2024 e i rapporti trimestrali al 31 marzo 2025 e al 30 giugno 2025. La dichiarazione di registrazione è stata firmata il 13 agosto 2025 dall'amministratore delegato Deborah L. Birx.

Armata Pharmaceuticals presentó un Formulario S-8 para registrar un adicional 1,811,295 acciones ordinarias para emisión bajo su 2016 Equity Incentive Plan y 2016 Employee Stock Purchase Plan. Las acciones se desglosan en 1,809,153 acciones añadidas al Equity Incentive Plan y 2,142 acciones bajo el ESPP conforme a las disposiciones anuales 'evergreen' vigentes desde el 1 de enero de 2017 hasta el 1 de enero de 2026. La presentación incorpora declaraciones de registro S-8 anteriores y presentaciones recientes ante la SEC, incluido el Informe Anual correspondiente al ejercicio cerrado el 31 de diciembre de 2024 y los informes trimestrales del 31 de marzo de 2025 y del 30 de junio de 2025. La declaración de registro fue firmada el 13 de agosto de 2025 por la directora ejecutiva Deborah L. Birx.

Armata Pharmaceuticals� Form S-8� 제출하여 2016� 주식 인센티브 플랜 � 2016� 종업� 주식매입계획(ESPP)� 따라 추가 보통� 1,811,295주를 등록했습니다. 주식은 인센티브 플랜� 추가� 1,809,153주와 ESPP� 따른 2,142주로 구분되며, 이는 2017� 1� 1일부� 2026� 1� 1일까지 적용되는 연간 'evergreen' 규정� 따른 것입니다. 이번 제출에는 이전 S-8 등록서류와 최근 SEC 제출서류가 포함되며, 2024� 12� 31� 종료� 회계연도 연례보고서와 2025� 3� 31� � 2025� 6� 30� 분기보고서가 포함됩니�. 등록서류� 최고경영�(CEO) 데보� L. 버릭스가 2025� 8� 13� 서명했습니다.

Armata Pharmaceuticals a déposé un formulaire S-8 pour enregistrer 1,811,295 actions ordinaires supplémentaires à émettre au titre de son 2016 Equity Incentive Plan et de son 2016 Employee Stock Purchase Plan. Ces actions se répartissent en 1,809,153 actions ajoutées à l'Equity Incentive Plan et 2,142 actions pour le ESPP, conformément aux dispositions annuelles 'evergreen' en vigueur du 1er janvier 2017 au 1er janvier 2026. Le dépôt incorpore des déclarations S-8 antérieures et des documents récents déposés auprès de la SEC, notamment le rapport annuel pour l'exercice clos le 31 décembre 2024 et les rapports trimestriels au 31 mars 2025 et au 30 juin 2025. La déclaration d'enregistrement a été signée le 13 août 2025 par la directrice générale Deborah L. Birx.

Armata Pharmaceuticals reichte ein Formular S-8 ein, um zusätzlich 1,811,295 Stammaktien zur Ausgabe im Rahmen ihres 2016 Equity Incentive Plan und des 2016 Employee Stock Purchase Plan zu registrieren. Die Aktien verteilen sich auf 1,809,153 Aktien, die dem Equity Incentive Plan hinzugefügt werden, und 2,142 Aktien für das ESPP gemäß den jährlichen 'evergreen'-Bestimmungen, die vom 1. Januar 2017 bis zum 1. Januar 2026 gelten. Die Einreichung bezieht frühere S-8-Registrierungserklärungen und jüngste SEC-Meldungen ein, darunter den Jahresbericht für das zum 31. Dezember 2024 endende Geschäftsjahr sowie die Quartalsberichte zum 31. März 2025 und zum 30. Juni 2025. Die Registrierungsanzeige wurde am 13. August 2025 von der Geschäftsführerin Deborah L. Birx unterzeichnet.

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM S-8

 

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

 

ARMATA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Washington 91-1549568

(State or other jurisdiction of

incorporation or organization) 

(I.R.S. Employer

Identification No.) 

 

5005 McConnell Avenue

Los Angeles, CA 90066

(Address of Principal Executive Offices) (Zip Code)

 

Armata Pharmaceuticals, Inc. 2016 Equity Incentive Plan

Armata Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan

 

(Full titles of the plans)

 

Armata Pharmaceuticals, Inc.

5005 McConnell Avenue

Los Angeles, CA 90066

(Name and address of agent for service)

 

(310) 655-2928

(Telephone number, including area code, of agent for service)

 

Copies to:

 

Deborah L. Birx

Armata Pharmaceuticals, Inc.

5005 McConnell Avenue

Los Angeles, CA 90066

(310) 655-2928

Jared Fertman

Willkie Farr & Gallagher LLP

787 Seventh Avenue

New York, New York 10019-6099

(212) 728-8000

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ¨   Accelerated filer ¨
Non-accelerated filer x    Smaller reporting company x
      Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

 

 

 

 

 

 

EXPLANATORY NOTE
REGISTRATION OF ADDITIONAL SHARES
PURSUANT TO GENERAL INSTRUCTION E

 

Pursuant to General Instruction E to Form S-8, this Registration Statement on Form S-8 (this “Registration Statement”) is filed by Armata Pharmaceuticals, Inc. (the “Registrant”) to register an additional 1,811,295 shares of the Registrant’s common stock, par value $0.01 per share (“Common Stock”), issuable under the Armata Pharmaceuticals, Inc. 2016 Equity Incentive Plan (the “Armata 2016 Plan”) or the Armata Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan (the “Armata 2016 ESPP”).  Such shares consist of the following:

 

·(i) 1,809,153 shares of Common Stock that were automatically added to the shares authorized for issuance under the Armata 2016 Plan on January 1, 2025, pursuant to an “evergreen” provision contained in the Armata 2016 Plan. Pursuant to such “evergreen” provision, on January 1st of each calendar year, from January 1, 2017 through and including January 1, 2026, the number of shares authorized for issuance under the Armata 2016 Plan is automatically increased by: (a) a number equal to 5% of the total number of shares of the Registrant’s capital stock outstanding on December 31st of the preceding calendar year, or (b) a lesser number of shares determined by the Registrant’s board of directors (the “Board”); and

 

·(ii) 2,142 shares of Common Stock that were automatically added to the shares authorized for issuance under the Armata 2016 ESPP on January 1, 2025, pursuant to an “evergreen” provision contained in the Armata 2016 ESPP. Pursuant to such provision, on January 1st of each calendar year, from January 1, 2017 through and including January 1, 2026, the number of shares authorized for issuance under the Armata 2016 ESPP is automatically increased by a number equal to the least of: (a) 1% of the total number of shares of the Registrant’s capital stock outstanding on December 31st of the preceding calendar year; (b) 2,142 shares; or (c) a number determined by the Board that is less than (a) and (b).

 

This Registration Statement hereby incorporates by reference the contents of the Registrant’s registration statement on Form S-8 filed with the Commission on January 23, 2024 (File No. 333-276657), November 15, 2023 (File No. 333-275580), June 22, 2016 (File No. 333-212183), May 1, 2017 (File No. 333-217563), November 14, 2017 (File No. 333-221564), March 28, 2018 (File No. 333-223987), and June 10, 2019 (File No. 333-232058), respectively (the “Prior Registration Statements”), in each case, to the extent not superseded hereby. The additional shares of Common Stock being registered by this Registration Statement are of the same class as those securities registered on the Prior Registration Statements.

 

PART I

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

 

All information required by Part I to be contained in the prospectus is omitted from this Registration Statement in accordance with Section 428 of the Securities Act of 1933, as amended (the “Securities Act”) and the instructions to Form S-8 and instead will be delivered, pursuant to Rule 428 under the Securities Act, to each participant in the Armata 2016 Plan and the Armata 2016 ESPP, as applicable.

 

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 3. Incorporation of Documents By Reference

 

This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which Registration Statements of the Registrant on Form S-8 relating to the same employee benefit plan are effective. Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.

 

- 2 -

 

 

The following documents, which we have filed with the Securities and Exchange Commission (the “Commission”), are incorporated by reference in this registration statement:

 

·The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 20, 2025;

 

·The Registrant’s Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2025 and June 30, 2025 filed with the Commission on May 14, 2025 and August 12, 2025;

 

·The Registrant’s Definitive Proxy Statement on Schedule 14A, filed with the Commission on April 28, 2025 (as amended and supplemented);

 

·The Registrant’s Current Reports on Form 8-K, filed with the Commission on March 12, 2025, April 2, 2025, May 1, 2025, June 13, 2025 and August 12, 2025 (only with respect to information filed under items 1.01, 2.03 and 9.01); and

 

·The description of our common stock contained in our registration statement on Form 8-A, filed with the Commission on August 18, 2015, including all amendments and reports filed for the purpose of updating such description.

 

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment that indicates that all shares of common stock offered hereby have been sold or which deregisters all shares of common stock then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with Commission rules shall not be deemed incorporated by reference into this registration statement.

 

Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this registration statement.

 

- 3 -

 

 

Item 8. Exhibits.

 

The following exhibits are filed herewith:

 

Exhibit    
Number   Exhibit Description
4.1   Amended and Restated Articles of Incorporation of the Company, as amended (incorporated by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q, filed with the SEC on November 16, 2015).
     
4.2   Articles of Amendment to Amended and Restated Articles of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K, filed with the SEC on April 24), 2017.
     
4.3   Statement of Correction to Articles of Amendment to Amended and Restated Articles of Incorporation of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q, filed on November 8, 2018).
     
4.4   Articles of Amendment to Amended and Restated Articles of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on December 18, 2018).
     
4.5   Articles of Amendment to Amended and Restated Articles of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on May 10, 2019).
     
4.6   Articles of Amendment to Amended and Restated Articles of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on December 11, 2019).
     
4.7   Articles of Amendment to Articles of Incorporation of the Company (effective March 26, 2020) (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on March 30, 2020).
     
4.8   Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.5 to the Company’s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2019).
     
4.9   Amendment to Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K, filed with the SEC on December 11, 2019).
     
4.10   Amendment to Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on February 26, 2020).
     
5.1   Opinion of Counsel
     
23.1   Consent of Independent Registered Public Accounting Firm
     
23.2   Consent of Counsel (included in Exhibit 5.1 to this Registration Stated and filed herewith)
     
24.1   Power of Attorney (included on the signature pages of this Registration Statement)
     
99.1   Armata Pharmaceuticals, Inc. 2016 Equity Incentive Plan, as amended incorporated by reference to Exhibit 99.1 to the registrant’s Registration Statement on Form S-8, filed with the SEC on June 10, 2019).
     
99.2   Armata Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 10.10 to the Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2019).
     
107   Filing Fee Table

 

- 4 -

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Los Angeles, State of California on August 13, 2025.

 

  Armata Pharmaceuticals, Inc.
   
  By: /s/ Deborah L. Birx
    Deborah L. Birx
    Chief Executive Officer

 

POWER OF ATTORNEY

 

Know All Persons By These Presents, that each person whose signature appears below constitutes and appoints each of Deborah L. Birx and David D. House as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

 

SIGNATURE   TITLE   DATE
         
/s/ Deborah L. Birx   Chief Executive Officer and Director   August 13, 2025
Deborah L. Birx, M.D.   (Principal Executive Officer)    
         
/s/ David D. House   Senior Vice President, Finance   August 13, 2025
David D. House   (Principal Financial Officer)    
         
/s/ Robin C. Kramer   Chair of the Board of Directors   August 13, 2025
Robin C. Kramer        
         
/s/ Jules Haimovitz   Director   August 13, 2025
Jules Haimovitz        
         
/s/ Odysseas D. Kostas   Director   August 13, 2025
Odysseas D. Kostas, M.D.        
         
/s/ Joseph M. Patti   Director   August 13, 2025
Joseph M. Patti, Ph.D.        
         
/s/ Todd C. Peterson   Director   August 13, 2025

Todd C. Peterson, Ph.D.

       
         
/s/ Sarah J. Schlesinger   Director   August 13, 2025

Sarah J. Schlesinger, M.D.

       

 

- 5 -

 

FAQ

What did Armata (ARMP) register on Form S-8?

Armata registered an additional 1,811,295 shares of common stock for issuance under its 2016 Equity Incentive Plan and 2016 ESPP.

How are the 1,811,295 shares allocated between plans?

The shares consist of 1,809,153 shares added to the Equity Incentive Plan and 2,142 shares added to the Employee Stock Purchase Plan.

Why were these additional shares added?

They were added pursuant to the plans' annual "evergreen" provisions that increase authorized shares each January 1 from 2017 through January 1, 2026.

Which recent SEC filings are incorporated by reference in this registration?

The filing incorporates the Annual Report for the year ended December 31, 2024 (filed March 20, 2025), quarterly reports for March 31, 2025 and June 30, 2025, the Definitive Proxy Statement filed April 28, 2025, and specified Current Reports filed in 2025.

Who signed the Form S-8 and when?

The Registration Statement was signed by Deborah L. Birx, Chief Executive Officer, on August 13, 2025.
Armata Pharmctcl

NYSE:ARMP

ARMP Rankings

ARMP Latest News

ARMP Latest SEC Filings

ARMP Stock Data

89.04M
11.02M
69.55%
2.13%
0.19%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
LOS ANGELES